Clinical Trials Logo

Transformed Lymphoma clinical trials

View clinical trials related to Transformed Lymphoma.

Filter by:

NCT ID: NCT05412290 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Start date: December 22, 2022
Phase: Phase 1
Study type: Interventional

This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.

NCT ID: NCT05281809 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Start date: April 19, 2022
Phase: Phase 2
Study type: Interventional

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

NCT ID: NCT05256641 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Start date: January 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT04796857 Recruiting - Clinical trials for High-grade B-cell Lymphoma

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Start date: March 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma

NCT ID: NCT04792489 Recruiting - Clinical trials for Central Nervous System Lymphoma

DALY II USA/ MB-CART2019.1 for DLBCL

Start date: May 25, 2021
Phase: Phase 2
Study type: Interventional

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.

NCT ID: NCT04545762 Recruiting - Clinical trials for Mantle Cell Lymphoma

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: September 11, 2020
Phase: Phase 1
Study type: Interventional

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

NCT ID: NCT04476459 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Start date: July 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

NCT ID: NCT04319237 Active, not recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Start date: March 10, 2020
Phase:
Study type: Observational

The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.

NCT ID: NCT04067414 Active, not recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Start date: June 14, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, dose-escalation phase 1 study to determine the safety and efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma.

NCT ID: NCT04058470 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Start date: April 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

1. Phase I portion of this study will evaluate the efficacy and saftey of toripalimab plus rituximab in treating untreated elderly diffuse large B cell lymphoma patients. 2. The aim of phase II portion of this study will evaluate the efficacy and saftey of toripalimab plus rituximab followed by R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen in treating untreated elderly diffuse large B cell lymphoma patients.